# US 2019/0002474 A1 · Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0002474 A1
- Document ID: US20190002474A1
- Status: Published application
- Kind: A1
- Application number: 15/535,860
- Filed: 2015-12-17
- Published: 2019-01-03
- Earliest claimed: 2014-12-17
- Assignees: Verrica Pharmaceuticals Inc.
- Applicants: Verrica Pharmaceuticals, Inc.
- Inventors: Matthew Davidson; Steven R. Schow
- Web page: https://patentgrep.com/patent/US20190002474A1

## CPC

- C07D 497/18: Bridged systems
- A61K 31/381: having five-membered rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 497/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

## Claims

### Claim 1

A method for generating a cantharidin formulation comprising cantharidin or a cantharidin derivative, the method comprising reacting a precursor of said cantharidin or cantharidin derivative to form said cantharidin formulation having said cantharidin or cantharidin derivative at an exo-to-endo ratio of at least 6:1.

### Claim at position 2

2-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein said reacting is conducted at a pressure less than about 100 atm.

### Claim at position 4

10-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein said precursor is selected from compound of formula (1), (2) or (3):

### Claim 14

A method for generating a cantharidin formulation comprising cantharidin or a cantharidin derivative, the method comprising reacting a precursor of said cantharidin or cantharidin derivative to form said cantharidin formulation having said cantharidin or cantharidin derivative, wherein said reacting is conducted (i) in the absence of diethyl ether, (ii) in the absence of a lithium or magnesium salt, and (iii) at a pressure less than about 980 atmospheres (atm).

### Claim at position 7

15-21. (canceled)

### Claim 22 (depends on 14)

The method of claim 14, wherein said reacting is conducted with the aid of a catalyst.

### Claim at position 9

23-24. (canceled)

### Claim 25 (depends on 22)

The method of claim 22, wherein said catalyst comprises bis(cyclopentadienyl)zirconium(IV) bis(trifluoromethanesulfonate)tetrahydrofuran complex.

### Claim 26 (depends on 22)

The method of claim 22, wherein said catalyst comprises aluminum chloride or boron trifluoride-diethyl etherate.

### Claim at position 12

27-29. (canceled)

### Claim 30

A cantharidin formulation comprising (i) cantharidin or a cantharidin derivative, (ii) less than 0.1% diethyl ether and (iii) less than 0.1% lithium salt, wherein said cantharidin or cantharidin derivative is at an exo-to-endo ratio of at least 6:1.

### Claim at position 14

31-36. (canceled)

### Claim 37

A cantharidin formulation comprising (i) cantharidin or a cantharidin derivative and (ii) a Lewis catalyst comprising one or more Lewis metals selected from the group consisting of Li (I), Mg (II), B (III), Al (III), Ti (IV), Zr (IV), Zn (II), Cu(I), Cu (II), Sn (II), Sn (IV), Si (IV), La (III), Sc (III), Yb (III), Eu (III), Ga (III), Sb (V), Nb (V), Fe (III), and Co (III), wherein said one or more Lewis metals are at concentration of at least about 1 part per billion (ppb).

### Claim at position 16

38-40. (canceled)

### Claim 41

A process for preparing cantharidin or a derivative thereof, comprising:
a) providing a first compound of formula (1):
b) forming a second compound having formula (2) from said first compound:
c) performing a cycloaddition reaction on said second compound to yield a third compound having formula (3):
and
d) generating said cantharidin or derivative thereof from said third compound.

### Claim at position 18

42-71. (canceled)

### Claim 72

A process, comprising:
a) providing a first compound of formula (1):
and
b) forming a second compound having formula (2):
from said first compound by subjecting said first compound to a hydrolysis reaction that is performed using NaOH.

### Claim 73

A process, comprising:
a) providing a first compound of formula (1):
and
b) forming a second compound having formula (2):
from said first compound by subjecting said first compound to a dehydration reaction that includes exposing said compound of formula (1) to an acyl halide.

### Claim 74

(canceled)

### Claim 75

A process, comprising:
a) providing a first compound of formula (1):
wherein X is selected from the group consisting of S, O, CH2, CHR1, CR1R2, NH, NR1, and NR1R2, wherein said R1 and R2 are each independently selected from an alkyl, aryl, heteroaryl, alkoxy, amine, alcohol, and halogen or together are a carbonyl, alkenyl, imine, or oxime, wherein said R1 and R2 are each optionally independently substituted; and
b) forming a second compound having formula (2):
wherein X is selected from the group consisting of S, O, CH2, CHR1, CR1R2, NH, NR1, and NR1R2, wherein said R1 and R2 are each independently selected from an alkyl, aryl, heteroaryl, alkoxy, amine, alcohol, and halogen or together are a carbonyl, alkenyl, imine, or oxime, wherein said R1 and R2 are each optionally independently substituted, from said first compound by subjecting said first compound to a cycloaddition reaction that includes exposing said first compound to at least one Lewis acid selected from the group consisting of Table 1, magnesium perchlorate, aluminum chloride, lithium trifluoromethanesulfonate, tin(II) trifluoromethanesulfonate, bis(cyclopentadienyl)zirconium(IV) bis(trifluoromethanesulfonate)tetrahydrofuran complex, bis(cyclopentadienyl)titanium(IV) bis(trifluoromethanesulfonate), boron trifluoride diethyl etherate, gallium(III) chloride, copper(II) tetrafluoroborate hydrate, aluminum bromide, niobium(V) chloride, ytterbium(III) trifluoromethanesulfonate, scandium(III) trifluoromethanesulfonate, magnesium trifluoromethanesulfonate, trimethylsilyl trifluoromethanesulfonate, and copper(II) trifluoromethanesulfonate.

### Claim at position 23

76-80. (canceled)

### Claim 81

A process for preparing cantharidin, comprising:
a) providing a first compound that is selected from any one of:
and
b) generating said cantharidin from said first compound by subjecting said first compound to a reduction reaction that includes hydrogenation and desulfurization reactions performed using separate reducing agents, wherein said desulfurization reaction is performed using a reducing agent selected from Table 2 that is not Raney Nickel.

### Claim at position 25

82-83. (canceled)

### Claim 84

A process, comprising:
a) providing a compound of formula (1) or (2):
and
b) forming a compound having a structure selected from the group consisting of
from said compound of formula (1) or (2) by subjecting said compound of formula (1) or (2) to an oxidation reaction.

### Claim 85

(canceled)

### Claim 86

A process, comprising:
a) providing a compound having a structure selected from the group consisting of
and
b) forming a compound having a structure selected from the group consisting of
from said compound provided in (a) by subjecting said compound provided in (a) to an oxidation reaction.

### Claim 87

(canceled)

### Claim 88

A composition having a structure selected from the group consisting of:

### Claim 89

A pharmaceutically acceptable mixture having a composition that is selected from any one of:

### Claim 90 (depends on 88)

A method of treating a subject, comprising administering to said subject a therapeutically effective amount of said pharmaceutically acceptable mixture according to claim 88.

### Claim 91 (depends on 90)

The method of claim 90, wherein said therapeutically effective amount is effective to treat Acral fibrokeratoma, Acrodermatitus enterpathica, Acrokeratoelastoidosis, Actinic keratosis (solar keratoses), Adenoma sebaceum, Angiokeratoma, Atopic Dermatitis, Basal cell carcinoma, Benign fibrous histiocytomas, Bladder cancer, Bowen's disease, Breast cancer, Buschke-Ollendorff syndrome, Cervical cancer, Cervical dysplasia, Cherry angiomas, Chondrodermatitis nodularis chronica helicis, Common warts, Cutaneous endometriosis, Cutaneous Leukemia, Cutaneous Lymphoma, Cutaneous meningioma, Cutaneous myxoma, Darier's disease, Dermal dendrocyte hamartoma, dermatofibroma, Dermatofibrosarcoma protuberans, Eccrine angiomatous hamartoma, Ectodermal dysplasia, Epidermal inclusion cysts, Epidermal Naevi, Epithelioid cell histiocytoma, Familial myxovascular fibromas, Fungal skin disease, Granular cell tumor, Glucaonoma syndrome, Genital warts, Ichthyosis, Idiopathic guttate hypomelanosis, Infantile acropustulosis, Infantile fibromatosis, Kaposi's sarcoma, Keloid, Keratoacanthoma, Keratocyst, Knuckle pads, Lentigo, Melanoma, Microvenular hemangioma, Molluscum contagiousum, Morton's neuroma, Multifocal lymphangioendotheliomatosis, Multinucleate cell angiohistocytoma, Multiple cutaneous leiomyomas, Mycosis fungoides, Neuroma cutis, Neurothekeoma, Nevus flammeus, Nevus lipomatosus superficialis, Pachydermodactyly, Palisaded encapsulated neuroma, Parasitic skin diseases, Pityriasis ruba pilaris, Piloleiomyomas, Plantar warts, Plexiform fibrohistiocytic tumor, Porokeratotic eccrine ostial and Dermal duct nevus, Progressive nodular histiocytoma Psoriasis, Porokeratosis, Seborrhoeic dermatitis, Seborrhoeic keratosis, Rhinophyma, Solitary cutaneous leiomyoma, Spider angioma, Targetoid hemosiderotic hemangioma, Squamous cell carcinoma, Tufted angioma, Venous lake, Urticaria pigmentosa, Xanthelasmoidal mastocytosis, Zosteriform metastasis, Benign epidermal cysts, Birthmarks, Calluses, Corns, Eczema, Freckles, Moles, Pigmentation disorders, Drug induced hyperpigmentation, Dyschromatosis symmetrica hereditaria, Dyschromatosis universalis hereditaria, Familial progressive hyperpigmentation, Galli-Galli disease, Hemosiderin hyperpigmentation, Idiopathic guttate hypomelanosis, Iron metallic discoloration, leukoderma, Melasma, Mukamel syndrome, Necklace of Venus, Nevus anemicus, Nevus depigmentosus, Pallister-Killian syndrome, Phylloid hypomelanosis, Piebaldism, Pigmentatio reticularis faciei et colli, Pilar Cysts, Pityriasis alba, Poikiloderma of Civatte, Poikiloderma vasculare atrophicans, Postinflammatory hyperpigmentation, Progressive macular hypomelanosis, Pruritus, Reticular pigmented anomaly of the flexures, Reticulate acropigmentation of Kitamura, Riehl melanosis, Shah-Waardenburg syndrome, Shiitake mushroom dermatitis, Tar melanosis, Titanium metallic discoloration, Transient neonatal pustular melanosis, Vagabond's leukomelanoderma, Vasospastic macules, Wende-Bauckus syndrome, X-linked reticulate pigmentary disorder, Yemenite deaf-blind hypopigmentation syndrome, Scars, Skin tags, Tattoo removal or Vitiligo.
